Tag: Zydus
Sterling Biotech to start world’s first precision fermentation-based dairy protein factory...
Spanning 27 acres, this state-of-the-art facility is expected to be operational by the first quarter of 2026
WHO prequalifies Zydus’s Typhoid Vi Conjugate Vaccine, ZyVac® TCV
Company receives acceptability, in principle, for ZyVac® TCV making it eligible for purchase by United Nations procurement agencies
Burkert inaugurates new manufacturing facility in Pune to strengthen its portfolio...
This state-of-the-art facility is a significant addition to Burkert’s global value chain, aimed at meeting the growing demand in the region by producing components and system solutions
CSIR-CDRI Lucknow and Zydus to develop best-in-class drug for CKD induced...
Under this agreement, CDRI and Zydus will jointly undertake preclinical research. Any drug candidate emerging from the efforts will be developed by Zydus for India and other markets
Zydus to acquire 50% stake in Sterling Biotech to enter into...
Post this transaction, Sterling Biotech will become a 50:50 Joint Venture with equal representation on the Board
Zydus secures Mexico’s COFEPRIS approval for its biosimilar ‘Bhava’ to treat...
Zydus Lifesciences receives approval to market Bhava™ for various cancers in Mexico, expanding access to affordable oncology treatments
Sentynl Therapeutics, a Zydus Group company announces global acquisition of Zokinvy
Zokinvy is approved in the US, European Union and Great Britain, and Japan for the treatment of Progeria, a collection of ultra-rare, fatal, genetic premature aging diseases that accelerate mortality in young patients
Zydus receives WHO’s approval for ‘Usnoflast’ as recommended name for ZYIL1
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Zydus gets USFDA nod for Phase II clinical trial of ZYIL1...
The Phase 2 study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics in patients with Parkinson’s Disease
Zydus acquires UK based LiqMeds
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026 depending on achievement of certain agreed milestones towards acquisition of the LiqMeds Group of companies